Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955424 | 0.80 | CA1 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22952850 | 0.79 | TDP1 (0.42) | CA1CA2CA12CA9CA14 | |
| SCHEMBL20087724 | 0.78 | PSIP1 (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL22952480 | 0.78 | MAPT (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7566986 | 0.76 | MAPT (0.43) | CA1CA2CA12CA9CA14 | |
| SCHEMBL5018973 | 0.76 | CA2 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL23260662 | 0.75 | BCHE (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL9190432 | 0.74 | CA1 (0.46) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18482578 | 0.74 | ACHE (0.47) | CA1CA2CA12CA9CA14 | |
| SCHEMBL24160936 | 0.73 | LMNA (0.44) | MAPTALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | DTYMK, TGFB1, DCK | CA1 4815/4885CA2 4687/4885CA12 4877/4885 |
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | GFPT1, QPCT, GLB1 | CA1 2979/4885CA2 2566/4885CA12 2557/4885 |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | TGFBR1, TGFBR2, TGFB1 | CA1 4634/4885CA2 3569/4885CA12 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.